Strategic Partners A/S

Strategic Partners A/S Financial Leverage

The Financial Leverage (Equity Multiplier) of Strategic Partners A/S (STRAP.CO) as of Oct 16, 2026 is 1.06. In the previous year, Financial Leverage (Equity Multiplier) was 1.22 — a change of -13.19% (lower).

Financial Leverage

1.06

YoY

-13.19%

Last updated:

Financial Leverage (Equity Multiplier) of Strategic Partners A/S is 2025 1.06 . Financial Leverage (Equity Multiplier) of Strategic Partners A/S was 2024 1.22 . It decreases by -13.19% lower compared to the previous year.

The Strategic Partners A/S Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.14 DKK
Jan 1, 2019
3.41 DKK
Jan 1, 2020
1.33 DKK
Jan 1, 2021
18.55 DKK
Jan 1, 2022
1.39 DKK
Jan 1, 2023
1.36 DKK
Jan 1, 2024
1.22 DKK
Jan 1, 2025
1.06 DKK
The Strategic Partners A/S Financial Leverage history
YEARFinancial LeverageYoY
1.06-13.19%
1.22-9.74%
1.36-2.23%
1.39-92.52%
18.55+1,299.42%
1.33-61.16%
3.41+200.19%
1.14+5.60%
1.08-40.99%
1.82+59.21%
1.15+7.41%
1.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strategic Partners A/S stock

Financial Leverage (Equity Multiplier) of Strategic Partners A/S is 1.06 in 2025.

Financial Leverage (Equity Multiplier) of Strategic Partners A/S changed from 1.22 to 1.06, representing a -13.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Strategic Partners A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Strategic Partners A/S

All Key Metrics — Strategic Partners A/S